TNFRSF4 and neoplasm: A bispecific antibody to CTLA-4 and OX40 has also been effective in pre-clinical models, reducing tumor growth and enhancing response to PD-1 targeted therapy, and is now in phase I clinical trials [NCT03782467] [84].